The genomics revolution is introducing fundamental changes in drug discovery enabling manufacture of better and safer drugs. The major impact of the drug discovery market is likely to be felt in the A
July 21, 2006 (Press Release) --
As budget for the pharmaceutical industry become constrained and lenient manufacturing gets more and more difficult the industry is pressed to develop drugs that comply with ‘real’ value. The evolution of the drug discovery procedure and introduction of more efficient processes that deliver higher percentage at a quicker pace paves way to the genomics revolution.
Ushering major changes in drug discovery the genomics revolution is producing clinical genomics solutions that focus on medical needs, research and development in pharmaceuticals and support development of improved and safer drugs. As the goals set for this industry become more striking and compelling, researchers are finding new ways and measures to ensure higher output.
Within the Asia Pacific drug market, fresh challenges mark their impact of which the regulatory procedures are major hurdles to the drug discovery process. Regulatory agencies are extremely cautious about new implementations to maintain efficiency and safety of drugs. This challenge is likely to make greater influence over the coming years. It has been found that in 2004, the Asia Pacific drug discovery market accounted for $5.7Bn, which is expected to touch $18.6Bn by 2011.
RNCOS through its market research report, “Bioinformatics Market Update (2006)” explains the rapid growth of Bioinformatics Industry Worldwide use of genomics technologies in the processes of drug screening, drug identification, and drug validation. It is estimated that the market will grow from $6.3Bn in 2002 to $19.5Bn by 2010.
The analysts at RNCOS also found that the global Bioinformatics market for instruments and services for certain drugs and allied products was worth $7.5Bn in 2000. Moving from then to 2005 the revenues increased to $14Bn at an AAGR of 12.0%.
The Research Report on Bioinformatics Industry provides answers for some critical questions relating to –
-- The current global outlook of Bioinformatics market;
-- The recent developments in the Bioinformatics industry worldwide;
-- The worldwide growth of the Genomics market;
-- The driving forces of the Bioinformatics market;
-- The opportunities for growth and impending threats for the industry; and
-- Comparison between different companies in the Bioinformatics market.
The report is a useful guide for the pharmaceutical companies, IT firms, biotechnology firms, prospective investors, students and academicians in the field of Bioinformatics.
About RNCOS:
RNCOS, incorporated in 2002, provides Market Research Reports for your business needs and aims to put an end to your information pursuit. Our expertise in gathering global business information for industry research, corporate training, growth consulting, and business consulting, brings reputed companies and firms to us for business enhancement solutions. We can be your one-stop-shop for Industry research information and niche market analysis.
To purchase your copy: http://rncos.com/Report/IM045.htm
For more information about the report please visit www.rncos.com
Ushering major changes in drug discovery the genomics revolution is producing clinical genomics solutions that focus on medical needs, research and development in pharmaceuticals and support development of improved and safer drugs. As the goals set for this industry become more striking and compelling, researchers are finding new ways and measures to ensure higher output.
Within the Asia Pacific drug market, fresh challenges mark their impact of which the regulatory procedures are major hurdles to the drug discovery process. Regulatory agencies are extremely cautious about new implementations to maintain efficiency and safety of drugs. This challenge is likely to make greater influence over the coming years. It has been found that in 2004, the Asia Pacific drug discovery market accounted for $5.7Bn, which is expected to touch $18.6Bn by 2011.
RNCOS through its market research report, “Bioinformatics Market Update (2006)” explains the rapid growth of Bioinformatics Industry Worldwide use of genomics technologies in the processes of drug screening, drug identification, and drug validation. It is estimated that the market will grow from $6.3Bn in 2002 to $19.5Bn by 2010.
The analysts at RNCOS also found that the global Bioinformatics market for instruments and services for certain drugs and allied products was worth $7.5Bn in 2000. Moving from then to 2005 the revenues increased to $14Bn at an AAGR of 12.0%.
The Research Report on Bioinformatics Industry provides answers for some critical questions relating to –
-- The current global outlook of Bioinformatics market;
-- The recent developments in the Bioinformatics industry worldwide;
-- The worldwide growth of the Genomics market;
-- The driving forces of the Bioinformatics market;
-- The opportunities for growth and impending threats for the industry; and
-- Comparison between different companies in the Bioinformatics market.
The report is a useful guide for the pharmaceutical companies, IT firms, biotechnology firms, prospective investors, students and academicians in the field of Bioinformatics.
About RNCOS:
RNCOS, incorporated in 2002, provides Market Research Reports for your business needs and aims to put an end to your information pursuit. Our expertise in gathering global business information for industry research, corporate training, growth consulting, and business consulting, brings reputed companies and firms to us for business enhancement solutions. We can be your one-stop-shop for Industry research information and niche market analysis.
To purchase your copy: http://rncos.com/Report/IM045.htm
For more information about the report please visit www.rncos.com
Email
Print
SPAM
LEAVE A COMMENT
